Eli Lilly presented its first batch of clinical data on developing next-generation FRα antibody-conjugated drugs for platinum-sensitive ovarian cancer at the 2026 European Society of Medical Oncology Annual Meeting.

Zhitongcaijing · 10/24 06:41
Eli Lilly presented its first batch of clinical data on developing next-generation FRα antibody-conjugated drugs for platinum-sensitive ovarian cancer at the 2026 European Society of Medical Oncology Annual Meeting.